CS
PCVX icon

Credit Suisse’s Vaxcyte PCVX Stock Holding History

Credit Suisse’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8.47M Buy
123,970
+26,167
+27% +$1.81M 0.01% 1003
2023
Q4 		$6.14M Buy
97,803
+11,591
+13% +$602K 0.01% 1217
2023
Q3 		$4.4M Sell
86,212
-7,443
-8% -$367K ﹤0.01% 1346
2023
Q2 		$4.68M Buy
93,655
+44,984
+92% +$2.13M ﹤0.01% 1383
2023
Q1 		$1.82M Buy
48,671
+5,666
+13% +$240K ﹤0.01% 1940
2022
Q4 		$2.06M Buy
43,005
+13,565
+46% +$532K ﹤0.01% 1853
2022
Q3 		$706K Buy
29,440
+5,543
+23% +$141K ﹤0.01% 2575
2022
Q2 		$520K Buy
23,897
+7,166
+43% +$166K ﹤0.01% 2813
2022
Q1 		$405K Sell
16,731
-359
-2% -$7.84K ﹤0.01% 3090
2021
Q4 		$406K Buy
17,090
+3,864
+29% +$89.9K ﹤0.01% 3965
2021
Q3 		$337K Buy
13,226
+1,916
+17% +$46.4K ﹤0.01% 4041
2021
Q2 		$254K Sell
11,310
-1,732
-13% -$35.5K ﹤0.01% 4187
2021
Q1 		$257K Sell
13,042
-20,694
-61% -$521K ﹤0.01% 4045
2020
Q4 		$895K Buy
+33,736
New +$1.25M ﹤0.01% 3408

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse's PCVX Position: Q1 2024 in Review

Credit Suisse increased its Vaxcyte (PCVX) stake by 27% in Q1 2024, buying an estimated $1.81M and bringing the position to 123,970 shares worth $8.47M. The position accounts for 0.01% of the portfolio, ranked #1003.

Credit Suisse first reported a position in PCVX in Q4 2020 and has held it in 14 quarters since. 251 funds tracked by Wall St. Rank hold PCVX as of Q1 2024.

  • Credit Suisse held 123,970 shares of Vaxcyte worth $8.47M as of Q1 2024.
  • Credit Suisse bought 26,167 Vaxcyte shares in Q1 2024, an estimated $1.81M.
  • Vaxcyte made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1003 holding.
  • Credit Suisse first reported a position in Vaxcyte in Q4 2020 and has held it in 14 quarters since.
  • 251 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.